Sign In
Buy SCD
$15.61
-0.0200 (-0.128%)
At Close: Jun 22, 2026
SCD: Gets The Job Done But Not The Most Efficient Income Fund
02:42am, Thursday, 18'th Jun 2026
LMP Capital and Income Fund maintains a 9.2% yield, with management expressing confidence in sustaining current distributions through August. Recent performance and distribution consistency have been
[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVYÂ (exagamglogene autotemcel
10 Best CEFs This Month: Average Yield Of 9% Plus (May 2026)
08:30am, Saturday, 23'rd May 2026
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9% plus yield and nearly 7.5% NAV discount. Selections emphasize sector d
Emmaus Life Sciences Reports Quarterly Financial Results
04:00pm, Friday, 15'th May 2026
Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its
LMP Capital and Income Fund Inc (NYSE: SCD) (the “Fund”) Announces Portfolio Management Team Update
08:00am, Friday, 17'th Apr 2026
NEW YORK--(BUSINESS WIRE)--Category: Fund Announcement.
Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor, potentially positioning Aramchol as a first-in-class therapy for synucleino
Allspring Global Investments Holdings LLC Makes New Investment in LMP Capital and Income Fund Inc. $SCD
03:22am, Friday, 10'th Apr 2026
Allspring Global Investments Holdings LLC purchased a new position in LMP Capital and Income Fund Inc. (NYSE: SCD) during the undefined quarter, according to its most recent disclosure with the Securi
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
07:30am, Thursday, 09'th Apr 2026
98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS). Galmed has developed, in collaboration with Barcod
SCD: Unique CEF Could Be Well-Positioned To Outperform In The Current Environment
12:20pm, Tuesday, 07'th Apr 2026
LMP Capital & Income Fund (SCD) offers a 9.63% yield, higher than broad equity indices and most peers, with a sustainable distribution profile. SCD's overweight energy allocation (14.05%) positions it
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data
Montreal, Quebec--(Newsfile Corp. - March 4, 2026) - Scandium Canada Ltée (TSXV: SCD) (la « Société ») est heureuse d'annoncer qu'en raison d'une forte demande des investisseurs, elle a conclu un
Scandium Canada Announces $10 Million Bought Deal Life Offering of Units
04:45pm, Tuesday, 03'rd Mar 2026
Montreal, Quebec--(Newsfile Corp. - March 3, 2026) - Scandium Canada Ltd. (TSXV: SCD) (the "Company") is pleased to announce that is has entered into an agreement with Research Capital Corporation ("R
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
08:10am, Saturday, 28'th Feb 2026
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversifica
Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (G
